EUCTR2015-003008-22-FI进行中（未招募）1 期
A Phase III, Randomized, Single Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trials V118_05 and V118_05E1 - aQIV re-vaccination study to evaluate safety and immunogenicity in children
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 486
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject’s parent/legal guardian has voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- •2. Male or female subjects from Season 1 of V118_05E1 who have completed their clinic Visit 13 (Day 366).
- •3. Subject whose treatment assignment in study V118_05E1 has remained blinded to the child and the child’s parent(s)/legal guardian(s).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 486
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Progressive, unstable or uncontrolled clinical conditions or any fatal condition (<12 month life expectancy).
- •2. History of epilepsy or convulsions (excluding febrile convulsions).
- •3. A subject who has any medical condition meeting the definition of AESI defined for the purposes of this trial (see Investigator Study File).
- •4. Individuals who have been diagnosed with any disorders in growth such as failure to thrive or short stature.
- •5. Subjects hospitalized at the time of enrollment.
- •6. Subjects with a history of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any vaccine component, to eggs (including ovalbumin), and
- •chicken protein, latex.
- •7. Subjects who have received antipyretic medication within the past 24 hours prior to vaccination. The subject may return for vaccination after a period of 24 hours has passed since the administration of an antipyretic.
- •8. Subjects who have had a fever [body temperature measurement = 38°C (= 100.4°F)] within three days prior to vaccination. The subject may return for vaccination after they have been free of fever for three days.
- •9. Previous immunization with any influenza vaccine (licensed or investigational) within 6 months prior to enrollment.
- •10. Subjects with a clinical condition representing a contraindication to intramuscular vaccination or blood draws.
- •11. Subjects who are children of research staff directly involved with the clinical study or who are otherwise related to research staff or have household members who are research staff. Research staff is individuals with direct or indirect contact with study subjects, or study site personnel who have access to any study documents containing subject information. This would include receptionists, persons scheduling appointments or making screening calls, regulatory specialists, laboratory technicians, etc.
- •12. Unwillingness of the parent(s)/ legal guardian(s) of the subject to refuse to participate in another clinical trial.
研究者
相似试验
已完成
3 期
A clinical trial to study the efficacy and safety of Montelukast and Fexofenadine fixed dose combination tablet Versus Fexofenadine tablet alone in the patients of Allergic Rhinitis.CTRI/2010/091/001300upin Limited India220
已完成
3 期
Comparison of Olmesartan +Amlodipine +Hydrochlorothiazide combination with Olmesartan +Hydrochlorothiazide combination in essential hypertension.CTRI/2010/091/006071Aristo Pharmaceuticals Pvt. Ltd. 23-Off veera desai road, Andheri W Mumbai-400053220
进行中（未招募）
不适用
A Phase III multicenter, single blind, randomized, comparative, add?on clinical trial, in three parallel groups, to evaluate the efficacy and safety of a new therapy with adipose?derived autologous stem cells for the treatment of complex perianal fistulas in patients without inflammatory bowel disease FATT I: Fistula Advanced Therapy Trial (I) - FATT 1Treatment of complex perianal fistulas in patients without inflammatory bowel disease.MedDRA version: 8.1Level: LLTClassification code 10002156Term: Anal fistulaEUCTR2006-003370-95-DECELLERIX, S.L.207
进行中（未招募）
不适用
A Phase III multicenter, single blind, randomized, comparative, add?on clinical trial, in three parallel groups, to evaluate the efficacy and safety of a new therapy with adipose?derived autologous stem cells for the treatment of complex perianal fistulas in patients without inflammatory bowel disease FATT I: Fistula Advanced Therapy Trial (I) - FATT 1Treatment of complex perianal fistulas in patients without inflammatory bowel disease.MedDRA version: 8.1Level: LLTClassification code 10002156Term: Anal fistulaEUCTR2006-003370-95-NLCELLERIX, S.L.207
进行中（未招募）
1 期
A Phase III multicenter, single blind, randomized, comparative, add?on clinical trial, in three parallel groups, to evaluate the efficacy and safety of a new therapy with adipose?derived autologous stem cells for the treatment of complex perianal fistulas in patients without inflammatory bowel disease FATT I: Fistula Advanced Therapy Trial (I)EUCTR2006-003370-95-ESCELLERIX, S.L.207